Bleakley Financial Group, LLC Biomarin Pharmaceutical Inc Transaction History

Bleakley Financial Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$74.43 - $92.22 $30,516 - $37,810	-410 Reduced 13.86%	2,548 $210 Million
Q1 2024 May 08, 2024	SELL	$83.81 - $99.0 $8,716 - $10,296	-104 Reduced 3.4%	2,958 $258 Million
Q4 2023 Jan 25, 2024	BUY	$76.22 - $98.51 $6,936 - $8,964	91 Added 3.06%	3,062 $295 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $19,395 - $21,541	228 Added 8.31%	2,971 $263 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $7,194 - $8,324	83 Added 3.12%	2,743 $238 Million
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $1.15 Million - $1.54 Million	-13,125 Reduced 83.15%	2,660 $259 Million
Q4 2022 Feb 07, 2023	BUY	$80.93 - $108.63 $1.28 Million - $1.71 Million	15,785 New	15,785 $1.63 Billion

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Bleakley Financial Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Bleakley Financial Group, LLC with notifications on news.